Dermavant to Present New Results of Tapinarof in P-III (PSOARING 3) Trial for the Treatment of Plaque Psoriasis at AAD 2022
Shots:
- The P-III (PSOARING 3) LTE study evaluating tapinarof (1%, qd) vs vehicle-controlled cream in 763 patients with PsO for ~40wks. & a 4wks. safety follow-up period. The patients had completed the treatment in the P-III (PSOARING 1 & 2) studies
- The results showed secondary efficacy data including change in percentage body surface area (%BSA) & PASI score by visit, PASI response rates (PASI75 & PASI90) @40wk. along with DLQI & local tolerability scores
- The US FDA has accepted an application for tapinarof to treat PsO in Aug 2021 & assigned a PDUFA date in Q2’22. Tapinarof is a non-steroidal, cosmetically elegant cream & a therapeutic aryl hydrocarbon receptor modulating agent for PsO & AD
Ref: Dermavant | Image: Dermavant
Click here to read the full press release